6-K

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2019

Commission File Number: 001-36187

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

13 Gad Feinstein Street

Park Rehovot P.O.B 2100

Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 A Slide Presentation: Canonic Company Introduction – April 2019.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 15, 2019 EVOGENE  LTD.(Registrant)By: /s/ Dorit Kreiner——————————————Dorit Kreiner Chief Financial Officer

3

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	A Slide Presentation: Canonic Company Introduction – April 2019.

4

EX-99.1

EXHIBIT 99.1

 Bringing precisionto medical cannabis             

 Safe harbor   This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “intend” and “potential” or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading “Risk Factors.” All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.  The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.  

 About us  Canonic is a fully owned subsidiary of Evogene Ltd* targeted to develop medical grade cannabis through a revolutionary approach utilizing disruptive genomic, big data and artificial intelligence technological platformFocused on improving yield and metabolite stability, and cannabis varieties for the main medical indications: PTSD, severe chronic pain and cancerHarnessing more than 10 years of Evogene’s experience and reputation in plant genomics, including collaborations with international ag companies - Bayer, Corteva, Monsanto, Syngenta, and othersExclusive access to Evogene’s CPB platform technology, IP and infrastructure for its cannabis R&D program including regulatory approvals for the establishment of a cannabis research facility*Evogene Ltd. – Publicly traded in TASE and NASDAQ (EVGN); Cash balance of > $50 Million (31/12/2018) 

 Agenda    Mission, Market & Challenges  Solution & Technology  Target Products & Business Plan  Assets & Capabilities   Summary           

 5    To develop and bring to marketmedical grade cannabisthrough a revolutionary genomic approach 

 The cannabis market  A fast growing market    Vast medical applications  Source: New frontier data (US only)  Source: Leafly Holdings 

 KEY CHALLENGES       Specific medical indications require tailored metabolite profiles. To date, breeding mainly pushed THC levels.  MEDICAL TAILORED PRODUCTS        Substantial variations within varieties produce inconsistent products that have become unreliable as a medical treatment.  VARIETY STABILITY  Low yields burden growers and patients with higher product and manufacturing costs.  METABOLITE YIELD    Relative St Dev (%)  THC  CBD  Potency (%)    per pound Production cost  $980  Annual average expenditure of medical cannabis user   $1,869 

 Agenda    Mission, Market & Challenges  Solution & Technology  Target Products & Business Plan  Assets & Capabilities   Summary           

 Our solution  Using computational power (AI, Big Data) to decode the cannabis genome and overcome market challenges         Essential gene  Current cannabis genetic mapping     Canonic: seeing the bigger picture  THC gene  CBD geneaffected  Essential genes                  Proprietary high yield genes        THC genes          CBD gene     

 Disruptive technology- the CPB Platform  Interconnected information hub   Artificial intelligence tools   Plant validation system  High quality data            Developed over >10 years  And more…  Understand plant genetics      Evogene’s Computational Predictive Biology (CPB) platform  Collaborations over the years with: 

 Agenda    Mission, Market & Challenges  Solution & Technology  Target Products & Business Plan  Assets & Capabilities   Summary           

        MetaYield+   Unican+   Precise+  Tailored METABOLITE PROFILES  Verified VARIETY STABILITY  Increased METABOLITE YIELD  Target products  Precise+ Chronic pain   Precise+ PTSD   Precise+ Cancer care   Innovative products to address key market needs  Cancer 5.9%  + For illustration purposes 

 Seed production   Varieties dev.      Cannabis growth   Formulation      Distribution  Business plan     Canonic will develop elite cannabis varieties for commercialization of medical products directly or via partnerships      Clinical validation & regulation         Unique varieties   Seeds  Flowers  Potential partnerships   

 Milestones roadmap   Establishment of R&D growing facility Complete two cannabis growth cyclesEstablish agronomic protocols Build cannabis core collectionEstablish initial cannabis database     2019   First product trait demonstrated Complete three cannabis growth cyclesComplete establishment of proprietary cannabis database Expand core collection of cannabis varieties    2020   Finalize development of first improved variety Pre-commercial stageSeed increase to allow production Finalize formulation process     2021  

 Agenda    Mission, Market & Challenges  Solution & Technology  Target Products & Business Plan  Assets & Capabilities   Summary           

 Interconnected information hub   Artificial intelligence tools   Plant validation system  High quality data            Understand plant genetics      Innovative technology implementation  Predictive biology   Plant systems  Science  Integrated data hub  IP  Select desired traits, avoid undesired effects  3*109 data points on 62 plant species   Novel genes and markers discovery capabilities  Greenhouses, tissue culture, molecular lab, phenotyping, statistics  Proprietary and public data, relevant for cannabis  Validated & patented genes for traits of interest(e.g. trichomes density, growth rate, flowering time)   

 Proprietary advantage   10y  Fast & efficient Can target any geneNon GMO, non genome editing    ADVANTAGES  Computational assisted new breeding technology  Classic breeding   Proven success -up to 30% improvement in oat*           Modify varieties    Design genetics  Selected genetic profile  Validate variety                                                                          *In greenhouse 

   KEY CHALLENGES       Specific medical indications require tailored metabolite profiles. To date, breeding mainly pushed THC levels.  MEDICAL TAILORED PRODUCTS        Substantial variations within varieties produce inconsistent products that have become unreliable as a medical treatment.  VARIETY STABILITY  Low yields burden growers and patients with higher product and manufacturing costs.  METABOLITE YIELD    Relative St Dev (%)  THC  CBD  Potency (%)    per pound Production cost  $980  Annual average expenditure of medical cannabis user   $1,869 

         Assets & capabilities from Evogene:Metabolites yield example  Cannabis metabolites are produced in small hairs (trichromes). We have proprietary IP for trichrome enhancement  Evogene has discovered genes for the improvement of trichomes density and/or length  >15 genes exhibited a significant impact on trichome traits in model plant systems  Cannabis yield is determined by its trichome population  Most of the genes are under granted patents     Trichomes in cannabis    Improved trichomes in tomato 

   KEY CHALLENGES       Specific medical indications require tailored metabolite profiles. To date, breeding mainly pushed THC levels.  MEDICAL TAILORED PRODUCTS        Substantial variations within varieties produce inconsistent products that have become unreliable as a medical treatment.  VARIETY STABILITY  Low yields burden growers and patients with higher product and manufacturing costs.  METABOLITE YIELD    Relative St Dev (%)  THC  CBD  Potency (%)    per pound Production cost  $980  Annual average expenditure of medical cannabis user   $1,869 

 Assets & capabilities from Evogene:Variety stability example  Current medical products are unreliable due to large fluctuations in active compounds levels  THE CHALLENGE      Development of stable cannabis varieties using advanced plant genomics capabilities  Advanced breeding - superior performanceHomogenous genomeHybrid seeds  THE SOLUTION  Underground breedingHigh genome heterogeneityConfusing varieties nomenclature   x  Smart selection process – identify genotypes using computational tools    Conducted by Evogene subsidiary on Castor  

 Assets & capabilities from Evogene:Variety stability example  Current medical products are unreliable due to large fluctuations in active compounds levels  THE CHALLENGE      Development of stable cannabis varieties using advanced plant genomics capabilities  THE SOLUTION  x  Smart selection process – identify genotypes using computational tools        Conducted by Evogene subsidiary on Castor  

   KEY CHALLENGES       Specific medical indications require tailored metabolite profiles. To date, breeding mainly pushed THC levels.  MEDICAL TAILORED PRODUCTS        Substantial variations within varieties produce inconsistent products that have become unreliable as a medical treatment.  VARIETY STABILITY  Low yields burden growers and patients with higher product and manufacturing costs.  METABOLITE YIELD    Relative St Dev (%)  THC  CBD  Potency (%)    per pound Production cost  $980  Annual average expenditure of medical cannabis user   $1,869 

 Assets & capabilities from Evogene:Metabolite profiles example    Metabolite        Proprietary Algorithms    Clinical indication   A  B  C  D  E  F  …  I  II  III  VI  V  VI  …  Connecting specific metabolites to clinical indications for precision medical cannabis products       Clinical data  Plant data    Input data  Output        Novel insect control genes  A machine learning approach  Genomic data    Public data  Genomic data 

 The team   Chairman  Ofer Haviv   Dr. Inbal Dangoor R&D  Ofir HazutStrategy & BD   Director of business development Evogene MEway Pharma, DiagnosticAid Medical,PeriTech PharmaMSc Neuroscience, MBA  Management  VP and GM Ag seeds division Evogene,CTO BondX technologiesPhD Biotechnology, MBA  Biotech Trait Manager, Ag seeds division Evogene PhD Plant science   Evogene CEO and President   Dr. Arnon HeymanCEO 

 Agenda    Mission, Market and Challenges  Solution & Technology  Target Products & Business Plan  Assets & Capabilities   Summary            

 Summary   Canonic’s mission is to develop and bring to market medical grade cannabis through a revolutionary genomic approachThe cannabis market is growing at a rapid pace, while the main market challenges are – yield, stability and tailored products for specific indicationsHarnessing more than 10 years of Evogene’s experience and reputation in plant genomics, including collaborations with international ag companies - Bayer, Corteva, Monsanto, Syngenta, and othersExclusive access to Evogene’s CPB platform technology, IP and infrastructure for its cannabis R&D program including regulatory approvals for the establishment of a cannabis research facility 

 Bringing precisionto medical cannabis